Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Mar. 26, 2015 | Jun. 30, 2014 | |
Document Type | 10-K | ||
Amendment Flag | FALSE | ||
Document Period End Date | 31-Dec-14 | ||
Trading Symbol | igxt | ||
Entity Registrant Name | IntelGenx Technologies Corp. | ||
Entity Central Index Key | 1098880 | ||
Current Fiscal Year End Date | -19 | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Common Stock, Shares Outstanding | 63,465,256 | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well Known Seasoned Issuer | No | ||
Entity Public Float | $39,745,692 | ||
Document Fiscal Year Focus | 2014 | ||
Document Fiscal Period Focus | FY |
Consolidated_Balance_Sheet
Consolidated Balance Sheet (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Current | ||
Cash and cash equivalents | $4,399 | $5,005 |
Accounts receivable | 652 | 144 |
Prepaid expenses | 96 | 133 |
Investment tax credits receivable | 108 | 268 |
Total Current Assets | 5,255 | 5,550 |
Leasehold Improvements and Equipment | 983 | 588 |
Intangible Assets | 46 | 79 |
Total Assets | 6,284 | 6,217 |
Current | ||
Accounts payable and accrued liabilities | 466 | 593 |
Deferred license revenue | 1,245 | 308 |
Total Current Liabilities | 1,711 | 901 |
Deferred License Revenue, non-current portion | 0 | 308 |
Total Liabilities | 1,711 | 1,209 |
Commitments | 0 | 0 |
Shareholders' Equity | ||
Capital Stock | 1 | 1 |
Additional Paid-in-Capital | 22,654 | 20,934 |
Accumulated Deficit | -17,848 | -16,102 |
Accumulated Other Comprehensive Income (Loss) | -234 | 175 |
Total Shareholders' Equity | 4,573 | 5,008 |
Total Liabilities and Stockholders' Equity | $6,284 | $6,217 |
Consolidated_Statement_of_Shar
Consolidated Statement of Shareholders' Equity (USD $) | Capital Stock [Member] | Additional Paid-In Capital [Member] | Accumulated Deficit [Member] | Accumulated Other Comprehensive Income [Member] | Total |
In Thousands, except Share data | |||||
Beginning Balance at Dec. 31, 2012 | $0 | $16,342 | ($14,463) | $299 | $2,178 |
Beginning Balance (Shares) at Dec. 31, 2012 | 49,890,421 | ||||
Foreign currency translation adjustment | -124 | -124 | |||
Issue of common stock, net of transaction costs of $387 | 1,808 | 1,808 | |||
Issue of common stock, net of transaction costs of $387 (Shares) | 7,920,346 | ||||
Warrants issued, net of transaction costs of $230 | 1,075 | 1,075 | |||
Agents' Warrants | 100 | 100 | |||
Warrants exercised | 1 | 1,464 | 1,465 | ||
Warrants exercised (Shares) | 3,098,500 | ||||
Options exercised | 31 | 31 | |||
Options exercised (Shares) | 75,000 | ||||
Stock-based compensation | 114 | 114 | |||
Net loss for the period | -1,639 | -1,639 | |||
Ending Balance at Dec. 31, 2013 | 1 | 20,934 | -16,102 | 175 | 5,008 |
Ending Balance (Shares) at Dec. 31, 2013 | 60,984,267 | ||||
Foreign currency translation adjustment | -409 | -409 | |||
Warrants exercised | 1,619 | 1,619 | |||
Warrants exercised (Shares) | 2,480,988 | ||||
Stock-based compensation | 101 | 101 | |||
Net loss for the period | -1,746 | -1,746 | |||
Ending Balance at Dec. 31, 2014 | $1 | $22,654 | ($17,848) | ($234) | $4,573 |
Ending Balance (Shares) at Dec. 31, 2014 | 63,465,255 |
Consolidated_Statement_of_Comp
Consolidated Statement of Comprehensive Loss (USD $) | 12 Months Ended | |
In Thousands, except Share data, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 |
Revenues | ||
Royalties | $476 | $188 |
License and other revenue | 1,183 | 760 |
Total Revenues | 1,659 | 948 |
Expenses | ||
Research and development expense | 1,075 | 561 |
Selling, general and administrative expense | 2,290 | 1,954 |
Depreciation of tangible assets | 35 | 34 |
Amortization of intangible assets | 39 | 38 |
Total Costs and Expenses | 3,439 | 2,587 |
Loss from Operations | -1,780 | -1,639 |
Other Income | ||
Interest and other income | 34 | 0 |
Total Other Income | 34 | 0 |
Loss Before Income Taxes | -1,746 | -1,639 |
Income taxes | 0 | 0 |
Net Loss | -1,746 | -1,639 |
Other Comprehensive Loss | ||
Foreign currency translation adjustment | -409 | -124 |
Comprehensive Loss | ($2,155) | ($1,763) |
Basic and Diluted Weighted Average Number of Shares Outstanding | 63,182,224 | 54,023,739 |
Basic and Diluted Loss Per Common Share | ($0.03) | ($0.03) |
Consolidated_Statement_of_Cash
Consolidated Statement of Cash Flows (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2014 | Dec. 31, 2013 |
Funds Provided (Used) - Operating Activities | ||
Net loss | ($1,746) | ($1,639) |
Amortization and depreciation | 74 | 72 |
Stock-based compensation | 101 | 114 |
Total adjustments | -1,571 | -1,453 |
Changes in assets and liabilities | ||
Accounts receivable | -508 | 1,138 |
Prepaid expenses | 37 | -31 |
Investment tax credits receivable | 160 | -55 |
Accounts payable and accrued liabilities | -127 | -465 |
Deferred license revenue | 629 | -307 |
Net change in assets and liabilities | 191 | 280 |
Net cash used by operating activities | -1,380 | -1,173 |
Financing Activities | ||
Issuance of common stock and warrants | 0 | 3,500 |
Proceeds from exercise of warrants, agents' warrants and stock options | 1,619 | 1,496 |
Transaction costs | 0 | -517 |
Net cash provided by financing activities | 1,619 | 4,479 |
Investing Activities | ||
Additions to leasehold improvements and equipment | -403 | -266 |
Net Cash used in investing activities | -403 | -266 |
Increase (Decrease) in Cash and Cash Equivalents | -164 | 3,040 |
Effect of Foreign Exchange on Cash and Cash Equivalents | -442 | -94 |
Cash and Cash Equivalents | ||
Beginning of Year | 5,005 | 2,059 |
End of Year | $4,399 | $5,005 |
Basis_of_Presentation
Basis of Presentation | 12 Months Ended | |
Dec. 31, 2014 | ||
Basis of Presentation [Text Block] | 1 | Basis of Presentation |
IntelGenx Technologies Corp. (“IntelGenx” or the “Company”) prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“USA”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. | ||
The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated. | ||
The financial statements are expressed in U.S. funds. |
Nature_of_Business
Nature of Business | 12 Months Ended | |
Dec. 31, 2014 | ||
Nature of Business [Text Block] | 2 | Nature of Business |
IntelGenx was incorporated in the State of Delaware as Big Flash Corp. on July 27, 1999. On April 28, 2006 Big Flash Corp. completed, through the Canadian holding corporation, the acquisition of IntelGenx Corp., a company incorporated in Canada on June 15, 2003. | ||
IntelGenx is a pharmaceutical company focused on the research, development, and commercialization of pharmaceutical products based upon three proprietary delivery platforms, including an immediate release oral film “VersaFilm™”, a mucoadhesive tablet “AdVersa™”, and a multilayer controlled release tablet “VersaTab™”. The Company has an aggressive product development initiative that primarily focuses on addressing unmet market needs and focuses on utilization of the U.S. Food and Drug Administration’s (“FDA”) 505(b)(2) approval process to obtain more timely and efficient approval of new formulations of previously approved products. | ||
The Company’s product pipeline currently consists of 10 products in various stages of development from inception through commercialization, including products for the treatment of major depressive disorder, opioid dependence, hypertension, erectile dysfunction, migraine, schizophrenia, idiopathic pulmonary fibrosis, and pain management. Of the products currently under development, 6 utilize the VersaFilm™ technology, 2 utilize the VersaTab™ technology, and one utilizes the AdVersa™ technology. In accordance with contractual commitments and for reasons of confidentiality, the Company is unable to disclose either the indicated treatment behind two of the products under development. | ||
The Company’s first FDA-approved product, Forfivo XL®, was launched in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP. Forfivo XL® is indicated for the treatment of Major Depressive Disorder (MDD) and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo XL® is bupropion, the same active ingredient used in Wellbutrin XL®. |
Adoption_of_New_Accounting_Sta
Adoption of New Accounting Standards | 12 Months Ended | |
Dec. 31, 2014 | ||
Adoption of New Accounting Standards [Text Block] | 3 | Adoption of New Accounting Standards |
The FASB issued Update No. 2013-05, “Foreign Currency Matters (Topic 830)—Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”. The amendments in this Update resolve the diversity in practice about whether Subtopic 810-10, Consolidation—Overall, or Subtopic 830-30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, the amendments in this Update resolve the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. For public entities, the amendments in this ASU were effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations. | ||
The FASB issued Update No. 2013-07, “Presentation of Financial Statements – Liquidation Basis of Accounting”. The objective of this Update is to clarify when an entity should apply the liquidation basis of accounting and to provide principles for the measurement of assets and liabilities under the liquidation basis of accounting, as well as any required disclosures. These amendments were effective for entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013, and interim reporting periods therein. Entitles should apply the requirements prospectively from the day that liquidation becomes imminent. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations. | ||
The FASB issued Update No. 2013-11, “Income Taxes (Topic 740)—Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”. The amendments in this ASU provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. The amendments were effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and should be applied prospectively to all unrecognized tax benefits that exist at the effective date. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations. | ||
The FASB has issued ASU No. 2014-17 which provides an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. The amendments were effective on November 18, 2014. After the effective date, an acquired entity can make an election to apply the guidance to future change-in-control events or to its most recent change-in-control event. However, if the financial statements for the period in which the most recent change-incontrol event occurred have already been issued or made available to be issued, the application of this guidance would be a change in accounting principle. |
Significant_Accounting_Policie
Significant Accounting Policies | 12 Months Ended | ||
Dec. 31, 2014 | |||
Significant Accounting Policies [Text Block] | 4 | Summary of Significant Accounting Policies | |
Revenue Recognition | |||
The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, recorded as other revenue, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income. | |||
IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured. | |||
In August 2010, the Company entered into a joint development and commercialization agreement with RedHill Biopharma (“RedHill”), an Israeli company, for an anti-migraine product based upon the Company’s VersaFilm™ technology. In accordance with the terms of the agreement, RedHill made up-front and milestone payments in the aggregate amount of $800 thousand, of which $200 thousand was received by the Company in 2013 upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration. RedHill is required to make additional milestone payments of $500 thousand upon receipt of FDA marketing approval for the product, together with royalties and / or a share of profits upon commercialization. | |||
In December 2011, the Company entered into a co-development and commercialization agreement with Par Pharmaceutical, Inc. ("Par"), a US company, for a generic formulation of buprenorphine and naloxone Sublingual Film, utilizing the Company’s VersaFilm™ technology. The reference listed drug is Suboxone® (buprenorphine and naloxone) Sublingual Film and is indicated for the maintenance treatment of opioid dependence. In accordance with the terms of the agreement, IntelGenx has received upfront and milestone payments in the aggregate amount of $750 thousand, of which $250 thousand was received by the Company in 2014 following acceptance by the FDA of the ANDA submission. The agreement provides for additional, undisclosed, milestone payments, together with a share of profits upon commercialization. | |||
In February 2012, the Company entered into a license agreement with Edgemont Pharmaceuticals LLC (“Edgemont”), a US company, for the commercialization Forfivo XL® in the United States. In accordance with the terms of the agreement, IntelGenx has received upfront and milestone payments in the aggregate amount of $3.25 million to date, and will be eligible for additional milestones upon achieving certain sales and exclusivity targets of up to a further $26.5 million. | |||
In January 2014, the Company entered into another development and commercialization agreement with Par for two new products utilizing the Company’s VersaFilm™ technology. Under the terms of the agreement, Par has obtained certain exclusive rights to market and sell IntelGenx' products in the USA. In exchange IntelGenx received an undisclosed upfront payment and has received certain undisclosed development milestones and will receive additional milestone payments, together with a share of the profits, upon commercialization. In accordance with confidentiality clauses contained in the agreement, the specifics of the product descriptions and financial terms of the transaction remain confidential. | |||
Product Sales: | |||
The Company launched Forfivo XL® in the USA in October 2012 under a licensing partnership with Edgemont. Under the terms of the license agreement, the commercial launch of Forfivo XL® triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company and recognized as revenue in the fourth quarter of 2012. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company commenced receiving royalties from sales of the product in the first quarter of 2013. Royalty income from sales of Forfivo XL® totaled $463 thousand in 2014 compared with $171 thousand in 2013. | |||
In the fourth quarter of 2014, Edgemont exercised its right to extend the license for the exclusive marketing of Forfivo XL®, for which the Company invoiced $1.25 million to Edgemont and recognized as deferred revenue, to be amortized in income from October 2014 through September 2015. In addition, upon entering into the licensing partnership, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue is being amortized in income over the period where sales of Forfivo XL® are expected to be exclusive. As a result of this policy, the Company recognized revenue in the aggregate amount of $621 thousand in 2014 and has a deferred revenue balance of $1.2 million at December 31, 2014 that has not been recognized as revenue. | |||
Use of Estimates | |||
The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants. | |||
Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions. | |||
Cash and Cash Equivalents | |||
Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value. | |||
Accounts Receivable | |||
The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible and records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2014 accounts receivable (2013: $Nil). | |||
Investment Tax Credits | |||
Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed. | |||
Leasehold Improvements and Equipment | |||
Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: | |||
On the declining balance method - | |||
Laboratory and office equipment | 20% | ||
Computer equipment | 30% | ||
On the straight-line method - | |||
Leasehold improvements | over the lease term | ||
Manufacturing equipment | 5 – 10 years | ||
Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred. | |||
Intangible Assets | |||
Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. | |||
Impairment of Long-lived Assets | |||
Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof. | |||
Foreign Currency Translation | |||
The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows: | |||
Assets and liabilities - at exchange rates in effect at the balance sheet date; | |||
Fixed assets - at historical rates Revenue and expenses - at average exchange rates prevailing during the year; | |||
Equity - at historical rates. | |||
Gains and losses arising from foreign currency translation are included in other comprehensive income. | |||
Income Taxes | |||
The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. | |||
Unrecognized Tax Benefits | |||
The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. | |||
Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision. | |||
Share-Based Payments | |||
The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options. | |||
The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year. | |||
Loss Per Share | |||
Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share. | |||
Fair Value Measurements | |||
ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: | |||
Level 1: | Quoted market prices in active markets for identical assets or liabilities. | ||
Level 2: | Observable market based inputs or unobservable inputs that are corroborated by market data. | ||
Level 3: | Unobservable inputs that are not corroborated by market data. | ||
In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2014. | |||
Fair Value of Financial Instruments | |||
The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization. | |||
Recent Accounting Pronouncements | |||
ASU 2014-15, Presentation of Financial Statements —Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern | |||
The FASB has issued ASU No. 2014-15 which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. This ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The amendments are effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently evaluating the impact of this update on its consolidated financial statements. | |||
ASU 2014-13, Consolidation (Topic 810): Measuring the Financial Assets and the Financial Liabilities of a Consolidated Collateralized Financing Entity | |||
The FASB has issued ASU No. 2014-13 which will apply to a reporting entity that is required to consolidate a collateralized financing entity under the Variable Interest Entities guidance. The fair value of the financial assets of a collateralized financing entity, as determined under GAAP, may differ from the fair value of its financial liabilities even when the financial liabilities have recourse only to the financial assets. Before this ASU, there was no specific guidance in GAAP on how a reporting entity should account for that difference. The amendments in this ASU provide an alternative to Topic 820, Fair Value Measurement, for measuring the financial assets and the financial liabilities of a consolidated collateralized financing entity to eliminate that difference. The amendments in this ASU are effective for public business entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted as of the beginning of an annual period. The adoption of ASU 2014-13 is not expected to have a material effect on the Company’s financial position or results of operations. | |||
ASU 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for shared-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. | |||
The FASB has issued ASU No. 2014-12 which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718, Compensation – Stock Compensation, as it relates to awards with performance conditions that affect vesting to account for such awards. The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The adoption of ASU-2014-12 is not expected to have material effect on the Company’s financial position or results of operations. | |||
ASU No. 2014-09, Revenues from Contracts with Customers (Topic 606) | |||
The FASB and IASB (the Boards) have issued converged standards on revenue recognition. ASU No. 2014-09 affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. This ASU will supersede the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: | |||
• | Step 1: Identify the contract(s) with a customer. | ||
• | Step 2: Identify the performance obligations in the contract. | ||
• | Step 3: Determine the transaction price. | ||
• | Step 4: Allocate the transaction price to the performance obligations in the contract. | ||
• | Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. | ||
For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. This ASU is to be applied retrospectively, with certain practical expedients allowed. Early application is not permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements. | |||
ASU No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. | |||
The FASB has issued ASU No. 2014-08 which enhance convergence between U.S. GAAP and International Financial Reporting Standards (IFRS). The amendments in the ASU change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in the ASU are effective in the first quarter of 2015 for public organizations with calendar year ends. Early adoption is permitted. The adoption of ASU-2014-08 is not expected to have material effect on the Company’s financial position or results of operations. |
Leasehold_Improvements_and_Equ
Leasehold Improvements and Equipment | 12 Months Ended | |||||||||||||
Dec. 31, 2014 | ||||||||||||||
Leasehold Improvements and Equipment [Text Block] | 5 | Leasehold Improvements and Equipment | ||||||||||||
2014 | 2013 | |||||||||||||
In US$ thousands | Accumulated | Net Carrying | Net Carrying | |||||||||||
Cost | Depreciation | Amount | Amount | |||||||||||
Manufacturing equipment | $ | 520 | $ | 0 | $ | 520 | $ | 446 | ||||||
Laboratory and office equipment | 570 | 329 | 241 | 121 | ||||||||||
Computer equipment | 57 | 42 | 15 | 11 | ||||||||||
Leasehold improvements - current premises | 63 | 63 | 0 | 0 | ||||||||||
Leasehold improvements - future premises | 207 | 0 | 207 | 10 | ||||||||||
$ | 1,417 | $ | 434 | $ | 983 | $ | 588 | |||||||
As of December 31, 2014 no depreciation has been recorded on manufacturing equipment as this equipment is being acquired for the Company’s new manufacturing facility and is therefore not currently in use. | ||||||||||||||
Leasehold improvements carried out on our current premises have been fully depreciated. IntelGenx has invested approximately $207 thousand related to leasehold improvement activities for new premises that the Company plans to occupy in the third quarter of 2015. Depreciation of this asset will commence upon occupation of the premises by the Company. |
Intangible_Assets
Intangible Assets | 12 Months Ended | |
Dec. 31, 2014 | ||
Intangible Assets [Text Block] | 6 | Intangible Assets |
As of December 31, 2014 NDA acquisition costs of $46 thousand (December 31, 2013: $79 thousand) were recorded as intangible assets on the Company’s balance sheet and represent the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL®. The asset is being amortized over its estimated useful life of 39 months and the Company commenced amortization upon commercial launch of the product in October 2012. |
Deferred_License_Revenue
Deferred License Revenue | 12 Months Ended | |
Dec. 31, 2014 | ||
Deferred License Revenue [Text Block] | 7 | Deferred License Revenue |
Deferred license revenue represents upfront payments received for the granting, or extension, of licenses to the Company’s patents, intellectual property, and proprietary technology, or to marketing rights, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur, or over the period for which the license is granted. | ||
Upon entering into the licensing agreement with Edgemont Pharmaceuticals the Company received an upfront fee of $1 million, which the Company recognized as deferred license revenue. This amount is being amortized in income over a period of 39 months, commencing October 2012, which is the minimum period where sales of Forfivo XL® are expected to be exclusive. | ||
In the fourth quarter of 2014, Edgemont exercised its right to extend the license for the exclusive marketing of Forfivo XL®. In accordance with the terms for exercising such right, IntelGenx invoiced $1.25 million to Edgemont and recognized the full amount as deferred revenue, to be amortized in income from October 2014 through September 2015. | ||
As at December 31, 2014, the Company has a deferred revenue balance of $1,245 thousand (December 31, 2013: $616 thousand) that has not been recognized as revenue. |
Commitments
Commitments | 12 Months Ended | |
Dec. 31, 2014 | ||
Commitments [Text Block] | 8 | Commitments |
The Company currently operates out of a 3,500 square feet leasehold facility consisting of laboratories and office space at 6425 Abrams, Saint-Laurent, Quebec. The monthly rent for this property is approximately $2 thousand. The original lease agreement expired in August 2009, since when it has been extended for varying periods. The most recent extension is defined as the day immediately preceding the fulfillment of certain conditions relating to the occupation of new leased premises at 6420 Abrams. | ||
On October 1, 2009, the Company signed an agreement with Little Gem Life Science Partners for investor relation services in the USA. Under the terms of the agreement, the Company was required to pay $4.5 thousand per month to Little Gem Life Science Partners. The Company renegotiated the agreement in May 2012 and reduced payments to $2.5 thousand per month. The agreement automatically renews unless specifically terminated. | ||
On May 7, 2010, the Company executed a Project Transfer Agreement with one of its former development partners whereby the Company acquired full rights to, and ownership of, Forfivo XL®, a novel, high strength formulation of Bupropion hydrochloride, the active ingredient in Wellbutrin XL®. In accordance with the Project Transfer Agreement, and following commercial launch of Forfivo XL® in October 2012, the Company is required, after recovering an aggregate $200 thousand for management fees previously paid, to pay its former development partner 10% of net income received from the sale of Forfivo XL®. In December 2014 the Company fully recovered said management fees and owed approximately $58 thousand to its former development partner that was remitted in February 2015. |
Capital_Stock
Capital Stock | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Capital Stock [Text Block] | 9 | Capital Stock | ||||||
2014 | 2013 | |||||||
Authorized - | ||||||||
100,000,000 common shares of $0.00001 par value | ||||||||
20,000,000 preferred shares of $0.00001 par value | ||||||||
Issued - | ||||||||
63,465,255 (December 31, 2013: 60,984,267) common shares | $ | 635 | $ | 610 | ||||
On December 16, 2013, as part of a registered public offering, the Company issued approximately 7.9 million shares of common stock at $0.4419 per share, and five-year warrants to purchase up to approximately 7.9 million shares of common stock, for aggregate gross proceeds of approximately US$3.5 million. Each warrant entitles the holder to purchase one common share at an exercise price of $0.5646 per common share and expires 60 months after the date of issuance. Proceeds were allocated between the common shares and the warrants based on their relative fair value. The common shares were recorded at a value of $1,808 thousand. (See note 10 for the portion allocated to the warrants). | ||||||||
The Company paid an agent cash commissions in the amount of approximately $210 thousand, representing 6% of the aggregate gross proceeds received by the Company, plus expenses in the amount of approximately $35 thousand, and issued warrants to the agent to purchase 475,221 shares of common stock, representing 6% of the amount of shares sold in the public offering. Each warrant entitles the holder to purchase one common share at an exercise price of $0.5646 per common share and expires 48 months after the date of issuance. | ||||||||
In addition, the Company paid approximately $272 thousand in cash consideration for other transaction costs, which have been reflected as a reduction of the common shares and the warrants based on their relative fair values. | ||||||||
No stock options were exercised in the year ended December 31, 2014. In the year ended December 31, 2013 a total of 75,000 stock options were exercised for 75,000 common shares having a par value of $0 thousand in aggregate, for cash consideration of $31 thousand, resulting in an increase in additional paid-in capital of $31 thousand. | ||||||||
In the year ended December 31, 2014 a total of 2,480,988 (2013: 3,098,500) warrants were exercised for 2,480,988 (2013: 3,098,500) common shares having a par value of $Nil (2013: $1 thousand) in aggregate, for cash consideration of approximately $1,619 thousand (2013: $1,465 thousand), resulting in an increase in additional paid-in capital of approximately $1,619 thousand (2013: $1,464 thousand). |
Additional_PaidIn_Capital
Additional Paid-In Capital | 12 Months Ended | ||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||
Additional Paid-In Capital [Text Block] | 10 | Additional Paid-In Capital | |||||||||||||||||||||
Stock Options | |||||||||||||||||||||||
In November 2006, the Company adopted the 2006 Stock Incentive Plan (the "Plan") for the purpose of issuing both Incentive Options and Nonqualified Options to officers, employees, directors and eligible consultants of the Company. A total of 1,600,749 shares of common stock were reserved for issuance under this plan. Options may be granted under the Plan on terms and at prices as determined by the Board of Directors except that the options cannot be granted at less than 100%, of the fair market value of the common stock on the date of the grant. Each option will be exercisable after the period or periods specified in the option agreement, but no option may be exercised after the expiration of 10 years from the date of grant. All options granted to individuals other than non-employee directors will have a total vesting period of 24 months from the date of grant, with one quarter of the total options granted vesting and becoming exercisable every six months. Options granted to non-employees may vest and become 100% fully exercisable immediately upon grant. | |||||||||||||||||||||||
In the second quarter of 2008, the life of the options was reduced from 10 years to 5 years to comply with the regulations of the Toronto Stock Exchange. Accordingly, because the grant-date fair value of the modified options was less than the fair value of the original options measured immediately before the modification, no incremental share-based compensation expense resulted from the modification. | |||||||||||||||||||||||
At the Annual General Meeting (“AGM”) on September 8, 2008 the shareholders of the Company approved an amendment to increase the number of shares available for issuance under the Plan from 1,600,749 to 2,074,000, or 10% of the Company’s issued and outstanding common shares as of July 28, 2008. Subsequent amendments were approved by the shareholders at the AGM’s held on June 3, 2010 and on May 7, 2013 to increase the number of shares available for issuance to 3,308,127 and 5,030,292 respectively. | |||||||||||||||||||||||
On April 24, 2013 the Company granted 480,000 stock options to an officer to purchase common shares. The stock options are exercisable at $0.65 per share and vest on December 31, 2015. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $157 thousand, using the following assumptions: | |||||||||||||||||||||||
Expected volatility | 78% | ||||||||||||||||||||||
Expected life | 3.83 years | ||||||||||||||||||||||
Risk-free interest rate | 0.34% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
On April 24, 2013 the Company granted 200,000 stock options to an officer to purchase common shares. The stock options are exercisable at $0.65 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $59 thousand, using the following assumptions: | |||||||||||||||||||||||
Expected volatility | 77% | ||||||||||||||||||||||
Expected life | 3.13 years | ||||||||||||||||||||||
Risk-free interest rate | 0.34% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
On August 6, 2013 the Company granted 35,000 stock options to a non-employee director to purchase common shares. The stock options are exercisable at $0.65 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $9 thousand, using the following assumptions: | |||||||||||||||||||||||
Expected volatility | 75% | ||||||||||||||||||||||
Expected life | 3.13 years | ||||||||||||||||||||||
Risk-free interest rate | 0.62% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
On December 3, 2013 the Company granted 75,000 stock options to a non-employee director to purchase common shares. The stock options are exercisable at $0.52 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $16 thousand, using the following assumptions: | |||||||||||||||||||||||
Expected volatility | 67% | ||||||||||||||||||||||
Expected life | 3.13 years | ||||||||||||||||||||||
Risk-free interest rate | 0.58% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
On December 3, 2013 the Company granted 100,000 stock options to an officer to purchase common shares. The stock options are exercisable at $0.52 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $21 thousand, using the following assumptions: | |||||||||||||||||||||||
Expected volatility | 67% | ||||||||||||||||||||||
Expected life | 3.13 years | ||||||||||||||||||||||
Risk-free interest rate | 0.58% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
On December 6, 2013 the Company granted an aggregate of 100,000 stock options to four employees to purchase common shares. The stock options are exercisable at $0.52 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $21 thousand, using the following assumptions: | |||||||||||||||||||||||
Expected volatility | 67% | ||||||||||||||||||||||
Expected life | 3.13 years | ||||||||||||||||||||||
Risk-free interest rate | 0.64% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
On December 8, 2014 the Company granted an aggregate of 175,000 stock options to three non-employee directors, two officers, and two employees to purchase common shares. The stock options are exercisable at $0.53 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $36 thousand, using the following assumptions: | |||||||||||||||||||||||
Expected volatility | 63% | ||||||||||||||||||||||
Expected life | 3.13 years | ||||||||||||||||||||||
Risk-free interest rate | 1.10% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
During the year ended December 31, 2013 a total of 75,000 stock options were exercised for 75,000 common shares having a par value of $0 thousand in aggregate, for cash consideration of $31 thousand, resulting in an increase in additional paid-in capital of $31 thousand. The intrinsic value of the stock options exercised, as at the dates of exercise, totaled $20 thousand. No stock options were exercised in the year ended December 31, 2014. | |||||||||||||||||||||||
Information with respect to employees and directors stock option activity for 2013 and 2014 is as follows: | |||||||||||||||||||||||
Weighted average | |||||||||||||||||||||||
Number of options | exercise price | ||||||||||||||||||||||
$ | |||||||||||||||||||||||
Outstanding – January 1, 2013 | 915,588 | 0.59 | |||||||||||||||||||||
Granted | 990,000 | 0.61 | |||||||||||||||||||||
Forfeited | (45,000 | ) | (0.48 | ) | |||||||||||||||||||
Expired | (238,088 | ) | (0.80 | ) | |||||||||||||||||||
Exercised | (25,000 | ) | (0.31 | ) | |||||||||||||||||||
Outstanding – December 31, 2013 | 1,597,500 | 0.58 | |||||||||||||||||||||
Granted | 175,000 | 0.53 | |||||||||||||||||||||
Forfeited | (517,500 | ) | (0.64 | ) | |||||||||||||||||||
Expired | (125,000 | ) | (0.61 | ) | |||||||||||||||||||
Exercised | - | - | |||||||||||||||||||||
Outstanding – December 31, 2014 | 1,130,000 | 0.54 | |||||||||||||||||||||
Information with respect to consultant’s stock option activity for 2013 and 2014 is as follows: | |||||||||||||||||||||||
Weighted average | |||||||||||||||||||||||
Number of options | exercise price | ||||||||||||||||||||||
$ | |||||||||||||||||||||||
Outstanding – January 1, 2013 | 150,000 | 0.55 | |||||||||||||||||||||
Granted | - | - | |||||||||||||||||||||
Forfeited | - | - | |||||||||||||||||||||
Expired | - | - | |||||||||||||||||||||
Exercised | (50,000 | ) | (0.47 | ) | |||||||||||||||||||
Outstanding – December 31, 2013 | 100,000 | 0.59 | |||||||||||||||||||||
Granted | - | - | |||||||||||||||||||||
Forfeited | - | - | |||||||||||||||||||||
Expired | - | - | |||||||||||||||||||||
Exercised | - | - | |||||||||||||||||||||
Outstanding – December 31, 2014 | 100,000 | 0.59 | |||||||||||||||||||||
Details of stock options outstanding as at December 31, 2014 are as follows: | |||||||||||||||||||||||
Outstanding options | Exercisable options | ||||||||||||||||||||||
Weighted | Weighted | ||||||||||||||||||||||
Weighted average | average | Aggregate | average | Aggregate | |||||||||||||||||||
Exercise | Number of | remaining | exercise | intrinsic | Number of | exercise | intrinsic | ||||||||||||||||
prices | options | contractual life | price | value | options | price | value | ||||||||||||||||
$ | (years) | $ | $ | $ | $ | ||||||||||||||||||
0.37 | 75,000 | 0.04 | 0.02 | 75,000 | 0.03 | ||||||||||||||||||
0.45 | 100,000 | 0.03 | 0.04 | 100,000 | 0.05 | ||||||||||||||||||
0.51 | 20,000 | 0.04 | 0.01 | 20,000 | 0.01 | ||||||||||||||||||
0.52 | 50,000 | 0.06 | 0.02 | 50,000 | 0.03 | ||||||||||||||||||
0.52 | 275,000 | 0.89 | 0.12 | 137,500 | 0.08 | ||||||||||||||||||
0.53 | 175,000 | 0.71 | 0.08 | - | - | ||||||||||||||||||
0.54 | 145,000 | 0.23 | 0.06 | 145,000 | 0.09 | ||||||||||||||||||
0.55 | 50,000 | 0.02 | 0.02 | 50,000 | 0.03 | ||||||||||||||||||
0.58 | 35,000 | 0.1 | 0.02 | 17,500 | 0.01 | ||||||||||||||||||
0.6 | 55,000 | 0.13 | 0.03 | 55,000 | 0.04 | ||||||||||||||||||
0.62 | 50,000 | 0.04 | 0.03 | 50,000 | 0.04 | ||||||||||||||||||
0.65 | 200,000 | 0.54 | 0.11 | 150,000 | 0.11 | ||||||||||||||||||
1,230,000 | 2.85 | 0.54 | 17,865 | 850,000 | 0.54 | 17,865 | |||||||||||||||||
Stock-based compensation expense recognized in 2014 with regards to the stock options was $101 thousand (2013: $114 thousand). As of December 31, 2014, total unrecognized compensation expense related to unvested stock options was $74 thousand (2013: $228 thousand), all of which relates to options granted to employees and directors. The amount of $74 thousand will be recognized as an expense over a period of two years. A change in control of the Company due to acquisition would cause the vesting of the stock options granted to employees and directors to accelerate and would result in $74 thousand being charged to stock based compensation expense. | |||||||||||||||||||||||
Warrants | |||||||||||||||||||||||
On December 16, 2013 the Company issued approximately 7.9 million stock purchase warrants exercisable into approximately 7.9 million common shares at $0.5646 per share which expire on December 16, 2018. The stock purchase warrants were issued in connection with the December 16, 2013 registered public offering described in note 9. The stock purchase warrants were valued at $1,305 thousand based on their relative fair value, as determined by the Black-Scholes valuation model using the assumptions below: | |||||||||||||||||||||||
Expected volatility | 80% | ||||||||||||||||||||||
Expected life | 5 years | ||||||||||||||||||||||
Risk-free interest rate | 1.55% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
On December 16, 2013 the Company issued approximately 0.5 million agents’ stock purchase warrants exercisable into approximately 0.5 million common shares at $0.5646 per share which expire on December 11, 2017. The stock purchase warrants were issued in connection with the December 16, 2013 registered public offering described in note 9. The stock purchase options were valued at $100 thousand based on their relative fair value, as determined by the Black-Scholes valuation model using the assumptions below: | |||||||||||||||||||||||
Expected volatility | 72% | ||||||||||||||||||||||
Expected life | 4 years | ||||||||||||||||||||||
Risk-free interest rate | 1.12% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
In the year ended December 31, 2014 a total of 2,480,988 warrants were exercised for 2,480,988 common shares having a par value of $Nil in aggregate, for cash consideration of approximately $1,619 thousand, resulting in an increase in additional paid-in capital of approximately $1,619 thousand. In the year ended December 31, 2013 a total of 3,098,500 warrants were exercised for 3,098,500 common shares having a par value of $1 thousand in aggregate, for cash consideration of approximately $1,465 thousand, resulting in an increase in additional paid-in capital of approximately $1,464 thousand. | |||||||||||||||||||||||
Information with respect to warrant activity for 2012 and 2013 is as follows: | |||||||||||||||||||||||
Number of | Weighted average | ||||||||||||||||||||||
warrants | exercise price | ||||||||||||||||||||||
(All Exercisable) | $ | ||||||||||||||||||||||
Outstanding – January 1, 2013 | 6,104,165 | 0.5938 | |||||||||||||||||||||
Warrants attached to registered public offering | 7,920,346 | 0.5646 | |||||||||||||||||||||
Agents’ warrants attached to registered public offering | 475,221 | 0.5646 | |||||||||||||||||||||
Exercised | (3,098,500 | ) | (0.4741 | ) | |||||||||||||||||||
Agents’ warrants expired | (257,500 | ) | (0.4741 | ) | |||||||||||||||||||
Outstanding - December 31, 2013 | 11,143,732 | 0.6079 | |||||||||||||||||||||
Exercised | (2,480,988 | ) | (0.6524 | ) | |||||||||||||||||||
Expired | (1,431,621 | ) | (0.7400 | ) | |||||||||||||||||||
Outstanding - December 31, 2014 | 7,231,123 | 0.5646 |
Income_Tax
Income Tax | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Income Tax [Text Block] | 11 | Income Taxes | ||||||
Income taxes reported differ from the amount computed by applying the statutory rates to losses. The reasons are as follows: | ||||||||
2014 | 2013 | |||||||
Statutory income taxes | $ | (429 | ) | $ | (442 | ) | ||
Net operating losses for which no tax benefits have been recorded | 238 | 278 | ||||||
Excess of depreciation over capital cost allowance | 9 | 11 | ||||||
Non-deductible expenses | 26 | 56 | ||||||
Undeducted research and development expenses | 181 | 142 | ||||||
Investment tax credit | (25 | ) | (45 | ) | ||||
$ | - | $ | - | |||||
The major components of the deferred tax assets classified by the source of temporary differences are as follows: | ||||||||
2014 | 2013 | |||||||
Leasehold improvements and equipment | $ | 9 | $ | 14 | ||||
Net operating losses carryforward | 2,582 | 2,407 | ||||||
Undeducted research and development expenses | 1,355 | 1,283 | ||||||
Non-refundable tax credits carryforward | 1,102 | 1,098 | ||||||
5,048 | 4,802 | |||||||
Valuation allowance | (5,048 | ) | (4,802 | ) | ||||
$ | - | $ | - | |||||
The valuation allowance at December 31, 2013 was $4,802 thousand. The net change in the valuation allowance during the period ended December 31, 2014, was an increase of $246 thousand. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2014. | ||||||||
There were Canadian and provincial net operating losses of approximately $9,530 thousand (2013: $8,874 thousand) and $9,683 thousand (2013: $9,040 thousand) respectively, that may be applied against earnings of future years. Utilization of the net operating losses is subject to significant limitations imposed by the change in control provisions. Canadian and provincial losses will be expiring between 2027 and 2034. A portion of the net operating losses may expire before they can be utilized. | ||||||||
As at December 31, 2014, the Company had non-refundable tax credits of $1,100 thousand (2013: $1,098 thousand) of which $20 thousand is expiring in 2017, $194 thousand is expiring in 2018, $170 thousand is expiring in 2019, $145 thousand is expiring in 2020, $154 thousand is expiring in 2021, $193 thousand is expiring in 2022, $129 thousand is expiring in 2023 and $95 thousand is expiring in 2024 and undeducted research and development expenses of $4,805 thousand (2013: $4,354 thousand) with no expiration date. | ||||||||
The deferred tax benefit of these items was not recognized in the accounts as it has been fully provided for. | ||||||||
Unrecognized Tax Benefits | ||||||||
The Company does not have any unrecognized tax benefits. | ||||||||
Tax Years and Examination | ||||||||
The Company files tax returns in each jurisdiction in which it is registered to do business. For each jurisdiction a statute of limitations period exists. After a statute of limitations period expires, the respective tax authorities may no longer assess additional income tax for the expired period. Similarly, the Company is no longer eligible to file claims for refund for any tax that it may have overpaid. The following table summarizes the Company’s major tax jurisdictions and the tax years that remain subject to examination by these jurisdictions as of December 31, 2014: | ||||||||
Tax Jurisdictions | Tax Years | |||||||
Federal - Canada | 2011 and onward | |||||||
Provincial - Quebec | 2011 and onward | |||||||
Federal - USA | 2011 and onward |
Statement_of_Cash_Flows_Inform
Statement of Cash Flows Information | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Statement of Cash Flows Information [Text Block] | 12 | Statement of Cash Flows Information | ||||||
In US$ thousands | 2014 | 2013 | ||||||
Additional Cash Flow Information: | ||||||||
Interest paid | $ | 5 | $ | 5 |
Related_Party_Transactions
Related Party Transactions | 12 Months Ended | |
Dec. 31, 2014 | ||
Related Party Transactions [Text Block] | 13 | Related Party Transactions |
Included in management salaries are $29 thousand (2013: $10 thousand) for options granted to the Chief Executive Officer, $Nil (2013: $39 thousand) for options granted to the Chief Operating Officer, and $43 thousand (2013: $29 thousand) for options granted to the Chief Financial Officer under the 2006 Stock Option Plan and $17 thousand (2013: $10 thousand) for options granted to non-employee directors. | ||
Included in general and administrative expenses are director fees of $187 thousand (2013: $80 thousand) comprising an annual stipend and for payments for attendance at board meetings and audit committee meetings. | ||
The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed upon by the related parties. |
Basic_and_Diluted_Loss_Per_Com
Basic and Diluted Loss Per Common Share | 12 Months Ended | |
Dec. 31, 2014 | ||
Basic and Diluted Loss Per Common Share [Text Block] | 14 | Basic and Diluted Loss Per Common Share |
Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants and stock options have been excluded from the calculation of diluted loss per share since they are anti-dilutive. |
Subsequent_Events
Subsequent Events | 12 Months Ended | |
Dec. 31, 2014 | ||
Subsequent Events [Text Block] | 15 | Subsequent Events |
Subsequent to the end of the year, on March 16, 2015 the Company received CAD$500 thousand (approximately $430 thousand) in cash as part of a credit facility of up to CAD$3.5 million (approximately $3.0 million) negotiated with BMO Bank of Montreal. The credit facility is supported by a 50% guarantee under the Export Guarantee Program from Export Development Canada. Disbursement of the remaining CAD$3.0 million ($2.6 million) is subject to review in August 2015 of the Company’s operating results for the first 6 months of 2015. The credit facility may be drawn down in multiple disbursements over 12 months and, after a 6 month moratorium on the capital, has a repayment term of up to 60 months. The Company will use the funds for the purchase and installation of new equipment for its new, state-of the-art, manufacturing facility. | ||
On March 16, 2015 the Company placed an order for 2 packaging machines to be manufactured and installed in the Company’s new, state-of the-art, manufacturing facility. The purchase order, in the aggregate amount of Euros 1.5 million (approximately $1.6 million), requires immediate payment of a 20% deposit with the balance to be paid upon completion of each machine. The laboratory packaging machine is expected to be delivered in Q3, 2015 and the commercial packaging machine is expected to be delivered in Q4, 2015. |
Summary_of_Significant_Account
Summary of Significant Accounting Policies (Policies) | 12 Months Ended | ||
Dec. 31, 2014 | |||
Revenue Recognition [Policy Text Block] | Revenue Recognition | ||
The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, recorded as other revenue, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income. | |||
IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured. | |||
In August 2010, the Company entered into a joint development and commercialization agreement with RedHill Biopharma (“RedHill”), an Israeli company, for an anti-migraine product based upon the Company’s VersaFilm™ technology. In accordance with the terms of the agreement, RedHill made up-front and milestone payments in the aggregate amount of $800 thousand, of which $200 thousand was received by the Company in 2013 upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration. RedHill is required to make additional milestone payments of $500 thousand upon receipt of FDA marketing approval for the product, together with royalties and / or a share of profits upon commercialization. | |||
Product Sales [Policy Text Block] | Product Sales: | ||
The Company launched Forfivo XL® in the USA in October 2012 under a licensing partnership with Edgemont. Under the terms of the license agreement, the commercial launch of Forfivo XL® triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company and recognized as revenue in the fourth quarter of 2012. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company commenced receiving royalties from sales of the product in the first quarter of 2013. Royalty income from sales of Forfivo XL® totaled $463 thousand in 2014 compared with $171 thousand in 2013. | |||
In the fourth quarter of 2014, Edgemont exercised its right to extend the license for the exclusive marketing of Forfivo XL®, for which the Company invoiced $1.25 million to Edgemont and recognized as deferred revenue, to be amortized in income from October 2014 through September 2015. In addition, upon entering into the licensing partnership, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue is being amortized in income over the period where sales of Forfivo XL® are expected to be exclusive. As a result of this policy, the Company recognized revenue in the aggregate amount of $621 thousand in 2014 and has a deferred revenue balance of $1.2 million at December 31, 2014 that has not been recognized as revenue. | |||
Use of Estimates [Policy Text Block] | Use of Estimates | ||
The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants. | |||
Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions. | |||
Cash and Cash Equivalents [Policy Text Block] | Cash and Cash Equivalents | ||
Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value. | |||
Accounts Receivable [Policy Text Block] | Accounts Receivable | ||
The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible and records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2014 accounts receivable (2013: $Nil). | |||
Investment Tax Credits [Policy Text Block] | Investment Tax Credits | ||
Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed. | |||
Leasehold Improvements and Equipment [Policy Text Block] | Leasehold Improvements and Equipment | ||
Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: | |||
On the declining balance method - | |||
Laboratory and office equipment | 20% | ||
Computer equipment | 30% | ||
On the straight-line method - | |||
Leasehold improvements | over the lease term | ||
Manufacturing equipment | 5 – 10 years | ||
Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred. | |||
Intangible Assets [Policy Text Block] | Intangible Assets | ||
Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. | |||
Impairment of Long-lived Assets [Policy Text Block] | Impairment of Long-lived Assets | ||
Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof. | |||
Foreign Currency Translation [Policy Text Block] | Foreign Currency Translation | ||
The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows: | |||
Assets and liabilities - at exchange rates in effect at the balance sheet date; | |||
Fixed assets - at historical rates Revenue and expenses - at average exchange rates prevailing during the year; | |||
Equity - at historical rates. | |||
Gains and losses arising from foreign currency translation are included in other comprehensive income. | |||
Income Taxes [Policy Text Block] | Income Taxes | ||
The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. | |||
Unrecognized Tax Benefits [Policy Text Block] | Unrecognized Tax Benefits | ||
The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. | |||
Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision. | |||
Share-Based Payments [Policy Text Block] | Share-Based Payments | ||
The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options. | |||
The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year. | |||
Loss Per Share [Policy Text Block] | Loss Per Share | ||
Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share. | |||
Fair Value Measurements [Policy Text Block] | Fair Value Measurements | ||
ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: | |||
Level 1: | Quoted market prices in active markets for identical assets or liabilities. | ||
Level 2: | Observable market based inputs or unobservable inputs that are corroborated by market data. | ||
Level 3: | Unobservable inputs that are not corroborated by market data. | ||
In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2014. | |||
Fair Value of Financial Instruments [Policy Text Block] | Fair Value of Financial Instruments | ||
The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization. | |||
Recently Issued Accounting Pronouncements [Policy Text Block] | Recent Accounting Pronouncements | ||
ASU 2014-15, Presentation of Financial Statements —Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern | |||
The FASB has issued ASU No. 2014-15 which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. This ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The amendments are effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently evaluating the impact of this update on its consolidated financial statements. | |||
ASU 2014-13, Consolidation (Topic 810): Measuring the Financial Assets and the Financial Liabilities of a Consolidated Collateralized Financing Entity | |||
The FASB has issued ASU No. 2014-13 which will apply to a reporting entity that is required to consolidate a collateralized financing entity under the Variable Interest Entities guidance. The fair value of the financial assets of a collateralized financing entity, as determined under GAAP, may differ from the fair value of its financial liabilities even when the financial liabilities have recourse only to the financial assets. Before this ASU, there was no specific guidance in GAAP on how a reporting entity should account for that difference. The amendments in this ASU provide an alternative to Topic 820, Fair Value Measurement, for measuring the financial assets and the financial liabilities of a consolidated collateralized financing entity to eliminate that difference. The amendments in this ASU are effective for public business entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted as of the beginning of an annual period. The adoption of ASU 2014-13 is not expected to have a material effect on the Company’s financial position or results of operations. | |||
ASU 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for shared-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. | |||
The FASB has issued ASU No. 2014-12 which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718, Compensation – Stock Compensation, as it relates to awards with performance conditions that affect vesting to account for such awards. The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The adoption of ASU-2014-12 is not expected to have material effect on the Company’s financial position or results of operations. | |||
ASU No. 2014-09, Revenues from Contracts with Customers (Topic 606) | |||
The FASB and IASB (the Boards) have issued converged standards on revenue recognition. ASU No. 2014-09 affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. This ASU will supersede the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: | |||
• | Step 1: Identify the contract(s) with a customer. | ||
• | Step 2: Identify the performance obligations in the contract. | ||
• | Step 3: Determine the transaction price. | ||
• | Step 4: Allocate the transaction price to the performance obligations in the contract. | ||
• | Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. | ||
For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. This ASU is to be applied retrospectively, with certain practical expedients allowed. Early application is not permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements. | |||
ASU No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. | |||
The FASB has issued ASU No. 2014-08 which enhance convergence between U.S. GAAP and International Financial Reporting Standards (IFRS). The amendments in the ASU change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in the ASU are effective in the first quarter of 2015 for public organizations with calendar year ends. Early adoption is permitted. The adoption of ASU-2014-08 is not expected to have material effect on the Company’s financial position or results of operations. |
Significant_Accounting_Policie1
Significant Accounting Policies (Tables) | 12 Months Ended | ||
Dec. 31, 2014 | |||
Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment [Table Text Block] | On the declining balance method - | ||
Laboratory and office equipment | 20% | ||
Computer equipment | 30% | ||
On the straight-line method - | |||
Leasehold improvements | over the lease term | ||
Manufacturing equipment | 5 – 10 years |
Leasehold_Improvements_and_Equ1
Leasehold Improvements and Equipment (Tables) | 12 Months Ended | |||||||||||||
Dec. 31, 2014 | ||||||||||||||
Schedule of Leasehold Improvements and Equipment [Table Text Block] | 2014 | 2013 | ||||||||||||
In US$ thousands | Accumulated | Net Carrying | Net Carrying | |||||||||||
Cost | Depreciation | Amount | Amount | |||||||||||
Manufacturing equipment | $ | 520 | $ | 0 | $ | 520 | $ | 446 | ||||||
Laboratory and office equipment | 570 | 329 | 241 | 121 | ||||||||||
Computer equipment | 57 | 42 | 15 | 11 | ||||||||||
Leasehold improvements - current premises | 63 | 63 | 0 | 0 | ||||||||||
Leasehold improvements - future premises | 207 | 0 | 207 | 10 | ||||||||||
$ | 1,417 | $ | 434 | $ | 983 | $ | 588 |
Capital_Stock_Tables
Capital Stock (Tables) | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Schedule of Stock by Class [Table Text Block] | 2014 | 2013 | ||||||
Authorized - | ||||||||
100,000,000 common shares of $0.00001 par value | ||||||||
20,000,000 preferred shares of $0.00001 par value | ||||||||
Issued - | ||||||||
63,465,255 (December 31, 2013: 60,984,267) common shares | $ | 635 | $ | 610 |
Additional_PaidIn_Capital_Tabl
Additional Paid-In Capital (Tables) | 12 Months Ended | ||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||
Schedule of 480,000 Stock Options Valuation - April 24, 2013 [Table Text Block] | Expected volatility | 78% | |||||||||||||||||||||
Expected life | 3.83 years | ||||||||||||||||||||||
Risk-free interest rate | 0.34% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
Schedule of 200,000 Stock Options Valuation - April 24, 2013 [Table Text Block] | Expected volatility | 77% | |||||||||||||||||||||
Expected life | 3.13 years | ||||||||||||||||||||||
Risk-free interest rate | 0.34% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
Schedule of 35,000 Stock Options Valuation - August 6, 2013 [Table Text Block] | Expected volatility | 75% | |||||||||||||||||||||
Expected life | 3.13 years | ||||||||||||||||||||||
Risk-free interest rate | 0.62% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
Schedule of 75,000 Stock Options Valuation - December 3, 2013 [Table Text Block] | Expected volatility | 67% | |||||||||||||||||||||
Expected life | 3.13 years | ||||||||||||||||||||||
Risk-free interest rate | 0.58% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
Schedule of 100,000 Stock Options Valuation - December 3, 2013 [Table Text Block] | Expected volatility | 67% | |||||||||||||||||||||
Expected life | 3.13 years | ||||||||||||||||||||||
Risk-free interest rate | 0.58% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
Schedule of 100,000 Stock Options Valuation - December 6, 2013 [Table Text Block] | Expected volatility | 67% | |||||||||||||||||||||
Expected life | 3.13 years | ||||||||||||||||||||||
Risk-free interest rate | 0.64% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
Schedule of 175,000 Stock Options Valuation - December 8, 2014 [Table Text Block] | Expected volatility | 63% | |||||||||||||||||||||
Expected life | 3.13 years | ||||||||||||||||||||||
Risk-free interest rate | 1.10% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
Schedule of Stock Option Activity to Employees and Directors[Table Text Block] | Weighted average | ||||||||||||||||||||||
Number of options | exercise price | ||||||||||||||||||||||
$ | |||||||||||||||||||||||
Outstanding – January 1, 2013 | 915,588 | 0.59 | |||||||||||||||||||||
Granted | 990,000 | 0.61 | |||||||||||||||||||||
Forfeited | (45,000 | ) | (0.48 | ) | |||||||||||||||||||
Expired | (238,088 | ) | (0.80 | ) | |||||||||||||||||||
Exercised | (25,000 | ) | (0.31 | ) | |||||||||||||||||||
Outstanding – December 31, 2013 | 1,597,500 | 0.58 | |||||||||||||||||||||
Granted | 175,000 | 0.53 | |||||||||||||||||||||
Forfeited | (517,500 | ) | (0.64 | ) | |||||||||||||||||||
Expired | (125,000 | ) | (0.61 | ) | |||||||||||||||||||
Exercised | - | - | |||||||||||||||||||||
Outstanding – December 31, 2014 | 1,130,000 | 0.54 | |||||||||||||||||||||
Schedule of Stock Option Activity to Consultant's [Table Text Block] | Weighted average | ||||||||||||||||||||||
Number of options | exercise price | ||||||||||||||||||||||
$ | |||||||||||||||||||||||
Outstanding – January 1, 2013 | 150,000 | 0.55 | |||||||||||||||||||||
Granted | - | - | |||||||||||||||||||||
Forfeited | - | - | |||||||||||||||||||||
Expired | - | - | |||||||||||||||||||||
Exercised | (50,000 | ) | (0.47 | ) | |||||||||||||||||||
Outstanding – December 31, 2013 | 100,000 | 0.59 | |||||||||||||||||||||
Granted | - | - | |||||||||||||||||||||
Forfeited | - | - | |||||||||||||||||||||
Expired | - | - | |||||||||||||||||||||
Exercised | - | - | |||||||||||||||||||||
Outstanding – December 31, 2014 | 100,000 | 0.59 | |||||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity [Table Text Block] | Outstanding options | Exercisable options | |||||||||||||||||||||
Weighted | Weighted | ||||||||||||||||||||||
Weighted average | average | Aggregate | average | Aggregate | |||||||||||||||||||
Exercise | Number of | remaining | exercise | intrinsic | Number of | exercise | intrinsic | ||||||||||||||||
prices | options | contractual life | price | value | options | price | value | ||||||||||||||||
$ | (years) | $ | $ | $ | $ | ||||||||||||||||||
0.37 | 75,000 | 0.04 | 0.02 | 75,000 | 0.03 | ||||||||||||||||||
0.45 | 100,000 | 0.03 | 0.04 | 100,000 | 0.05 | ||||||||||||||||||
0.51 | 20,000 | 0.04 | 0.01 | 20,000 | 0.01 | ||||||||||||||||||
0.52 | 50,000 | 0.06 | 0.02 | 50,000 | 0.03 | ||||||||||||||||||
0.52 | 275,000 | 0.89 | 0.12 | 137,500 | 0.08 | ||||||||||||||||||
0.53 | 175,000 | 0.71 | 0.08 | - | - | ||||||||||||||||||
0.54 | 145,000 | 0.23 | 0.06 | 145,000 | 0.09 | ||||||||||||||||||
0.55 | 50,000 | 0.02 | 0.02 | 50,000 | 0.03 | ||||||||||||||||||
0.58 | 35,000 | 0.1 | 0.02 | 17,500 | 0.01 | ||||||||||||||||||
0.6 | 55,000 | 0.13 | 0.03 | 55,000 | 0.04 | ||||||||||||||||||
0.62 | 50,000 | 0.04 | 0.03 | 50,000 | 0.04 | ||||||||||||||||||
0.65 | 200,000 | 0.54 | 0.11 | 150,000 | 0.11 | ||||||||||||||||||
1,230,000 | 2.85 | 0.54 | 17,865 | 850,000 | 0.54 | 17,865 | |||||||||||||||||
Schedule of Warrants Valuation - December 16, 2013 [Table Text Block] | Expected volatility | 80% | |||||||||||||||||||||
Expected life | 5 years | ||||||||||||||||||||||
Risk-free interest rate | 1.55% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
Schedule of 0.5 million Warrants Valuation - December 16, 2013 [Table Text Block] | Expected volatility | 72% | |||||||||||||||||||||
Expected life | 4 years | ||||||||||||||||||||||
Risk-free interest rate | 1.12% | ||||||||||||||||||||||
Dividend yield | nil | ||||||||||||||||||||||
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block] | Number of | Weighted average | |||||||||||||||||||||
warrants | exercise price | ||||||||||||||||||||||
(All Exercisable) | $ | ||||||||||||||||||||||
Outstanding – January 1, 2013 | 6,104,165 | 0.5938 | |||||||||||||||||||||
Warrants attached to registered public offering | 7,920,346 | 0.5646 | |||||||||||||||||||||
Agents’ warrants attached to registered public offering | 475,221 | 0.5646 | |||||||||||||||||||||
Exercised | (3,098,500 | ) | (0.4741 | ) | |||||||||||||||||||
Agents’ warrants expired | (257,500 | ) | (0.4741 | ) | |||||||||||||||||||
Outstanding - December 31, 2013 | 11,143,732 | 0.6079 | |||||||||||||||||||||
Exercised | (2,480,988 | ) | (0.6524 | ) | |||||||||||||||||||
Expired | (1,431,621 | ) | (0.7400 | ) | |||||||||||||||||||
Outstanding - December 31, 2014 | 7,231,123 | 0.5646 |
Income_Tax_Tables
Income Tax (Tables) | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2014 | 2013 | ||||||
Statutory income taxes | $ | (429 | ) | $ | (442 | ) | ||
Net operating losses for which no tax benefits have been recorded | 238 | 278 | ||||||
Excess of depreciation over capital cost allowance | 9 | 11 | ||||||
Non-deductible expenses | 26 | 56 | ||||||
Undeducted research and development expenses | 181 | 142 | ||||||
Investment tax credit | (25 | ) | (45 | ) | ||||
$ | - | $ | - | |||||
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 2014 | 2013 | ||||||
Leasehold improvements and equipment | $ | 9 | $ | 14 | ||||
Net operating losses carryforward | 2,582 | 2,407 | ||||||
Undeducted research and development expenses | 1,355 | 1,283 | ||||||
Non-refundable tax credits carryforward | 1,102 | 1,098 | ||||||
5,048 | 4,802 | |||||||
Valuation allowance | (5,048 | ) | (4,802 | ) | ||||
$ | - | $ | - |
Statement_of_Cash_Flows_Inform1
Statement of Cash Flows Information (Tables) | 12 Months Ended | |||||||
Dec. 31, 2014 | ||||||||
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] | In US$ thousands | 2014 | 2013 | |||||
Additional Cash Flow Information: | ||||||||
Interest paid | $ | 5 | $ | 5 |
Nature_of_Business_Narrative_D
Nature of Business (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2014 | |
Nature Of Business 1 | 10 |
Nature Of Business 2 | 6 |
Nature Of Business 3 | 2 |
Significant_Accounting_Policie2
Significant Accounting Policies (Narrative) (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
D | |
Significant Accounting Policies 1 | 45 |
Significant Accounting Policies 2 | $800,000 |
Significant Accounting Policies 3 | 200,000 |
Significant Accounting Policies 4 | 500,000 |
Significant Accounting Policies 5 | 750,000 |
Significant Accounting Policies 6 | 250,000 |
Significant Accounting Policies 7 | 3,250,000 |
Significant Accounting Policies 8 | 26,500,000 |
Significant Accounting Policies 9 | 4,000,000 |
Significant Accounting Policies 10 | 1,000,000 |
Significant Accounting Policies 11 | 23,500,000 |
Significant Accounting Policies 12 | 463,000 |
Significant Accounting Policies 13 | 171,000 |
Significant Accounting Policies 14 | 1,250,000 |
Significant Accounting Policies 15 | 1,000,000 |
Significant Accounting Policies 16 | 621,000 |
Significant Accounting Policies 17 | 1,200,000 |
Significant Accounting Policies 18 | $0 |
Significant Accounting Policies 19 | 50.00% |
Leasehold_Improvements_and_Equ2
Leasehold Improvements and Equipment (Narrative) (Details) (USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2014 |
Leasehold Improvements And Equipment 1 | $207 |
Intangible_Assets_Narrative_De
Intangible Assets (Narrative) (Details) (USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2014 |
M | |
Intangible Assets 1 | $46 |
Intangible Assets 2 | $79 |
Intangible Assets 3 | 100.00% |
Intangible Assets 4 | 39 |
Deferred_License_Revenue_Narra
Deferred License Revenue (Narrative) (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
M | |
Deferred License Revenue 1 | $1,000,000 |
Deferred License Revenue 2 | 39 |
Deferred License Revenue 3 | 1,250,000 |
Deferred License Revenue 4 | 1,245,000 |
Deferred License Revenue 5 | $616,000 |
Commitments_Narrative_Details
Commitments (Narrative) (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Commitments 1 | 3,500 |
Commitments 2 | 6,425 |
Commitments 3 | $2,000 |
Commitments 4 | 6,420 |
Commitments 5 | 4,500 |
Commitments 6 | 2,500 |
Commitments 7 | 200,000 |
Commitments 8 | 10.00% |
Commitments 9 | $58,000 |
Capital_Stock_Narrative_Detail
Capital Stock (Narrative) (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
M | |
Capital Stock 1 | 7,900,000 |
Capital Stock 2 | $0.44 |
Capital Stock 3 | 7,900,000 |
Capital Stock 4 | $3,500,000 |
Capital Stock 5 | 0.5646 |
Capital Stock 6 | 60 |
Capital Stock 7 | 1,808,000 |
Capital Stock 8 | 210,000 |
Capital Stock 9 | 6.00% |
Capital Stock 10 | 35,000 |
Capital Stock 11 | 475,221 |
Capital Stock 12 | 6.00% |
Capital Stock 13 | 0.5646 |
Capital Stock 14 | 48 |
Capital Stock 15 | 272,000 |
Capital Stock 16 | 75,000 |
Capital Stock 17 | 75,000 |
Capital Stock 18 | 0 |
Capital Stock 19 | 31,000 |
Capital Stock 20 | 31,000 |
Capital Stock 21 | 2,480,988 |
Capital Stock 22 | 3,098,500 |
Capital Stock 23 | 2,480,988 |
Capital Stock 24 | 3,098,500 |
Capital Stock 25 | 0 |
Capital Stock 26 | 1,000 |
Capital Stock 27 | 1,619,000 |
Capital Stock 28 | 1,465,000 |
Capital Stock 29 | 1,619,000 |
Capital Stock 30 | $1,464,000 |
Additional_PaidIn_Capital_Narr
Additional Paid-In Capital (Narrative) (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Y | |
M | |
Additional Paid-in Capital 1 | 1,600,749 |
Additional Paid-in Capital 2 | 100.00% |
Additional Paid-in Capital 3 | 10 |
Additional Paid-in Capital 4 | 24 |
Additional Paid-in Capital 5 | 100.00% |
Additional Paid-in Capital 6 | 10 |
Additional Paid-in Capital 7 | 5 |
Additional Paid-in Capital 8 | 1,600,749 |
Additional Paid-in Capital 9 | 2,074,000 |
Additional Paid-in Capital 10 | 10.00% |
Additional Paid-in Capital 11 | 3,308,127 |
Additional Paid-in Capital 12 | 5,030,292 |
Additional Paid-in Capital 13 | 480,000 |
Additional Paid-in Capital 14 | $0.65 |
Additional Paid-in Capital 15 | $157,000 |
Additional Paid-in Capital 16 | 200,000 |
Additional Paid-in Capital 17 | $0.65 |
Additional Paid-in Capital 18 | 2 |
Additional Paid-in Capital 19 | 25.00% |
Additional Paid-in Capital 20 | 59,000 |
Additional Paid-in Capital 21 | 35,000 |
Additional Paid-in Capital 22 | $0.65 |
Additional Paid-in Capital 23 | 2 |
Additional Paid-in Capital 24 | 25.00% |
Additional Paid-in Capital 25 | 9,000 |
Additional Paid-in Capital 26 | 75,000 |
Additional Paid-in Capital 27 | $0.52 |
Additional Paid-in Capital 28 | 2 |
Additional Paid-in Capital 29 | 25.00% |
Additional Paid-in Capital 30 | 16,000 |
Additional Paid-in Capital 31 | 100,000 |
Additional Paid-in Capital 32 | $0.52 |
Additional Paid-in Capital 33 | 2 |
Additional Paid-in Capital 34 | 25.00% |
Additional Paid-in Capital 35 | 21,000 |
Additional Paid-in Capital 36 | 100,000 |
Additional Paid-in Capital 37 | $0.52 |
Additional Paid-in Capital 38 | 2 |
Additional Paid-in Capital 39 | 25.00% |
Additional Paid-in Capital 40 | 21,000 |
Additional Paid-in Capital 41 | 175,000 |
Additional Paid-in Capital 42 | $0.53 |
Additional Paid-in Capital 43 | 2 |
Additional Paid-in Capital 44 | 25.00% |
Additional Paid-in Capital 45 | 36,000 |
Additional Paid-in Capital 46 | 75,000 |
Additional Paid-in Capital 47 | 75,000 |
Additional Paid-in Capital 48 | 0 |
Additional Paid-in Capital 49 | 31,000 |
Additional Paid-in Capital 50 | 31,000 |
Additional Paid-in Capital 51 | 20,000 |
Additional Paid-in Capital 52 | 101,000 |
Additional Paid-in Capital 53 | 114,000 |
Additional Paid-in Capital 54 | 74,000 |
Additional Paid-in Capital 55 | 228,000 |
Additional Paid-in Capital 56 | 74,000 |
Additional Paid-in Capital 57 | 74,000 |
Additional Paid-in Capital 58 | 7,900,000 |
Additional Paid-in Capital 59 | 7,900,000 |
Additional Paid-in Capital 60 | $0.56 |
Additional Paid-in Capital 61 | 1,305,000 |
Additional Paid-in Capital 62 | 500,000 |
Additional Paid-in Capital 63 | 500,000 |
Additional Paid-in Capital 64 | $0.56 |
Additional Paid-in Capital 65 | 100,000 |
Additional Paid-in Capital 66 | 2,480,988 |
Additional Paid-in Capital 67 | 2,480,988 |
Additional Paid-in Capital 68 | 0 |
Additional Paid-in Capital 69 | 1,619,000 |
Additional Paid-in Capital 70 | 1,619,000 |
Additional Paid-in Capital 71 | 3,098,500 |
Additional Paid-in Capital 72 | 3,098,500 |
Additional Paid-in Capital 73 | 1,000 |
Additional Paid-in Capital 74 | 1,465,000 |
Additional Paid-in Capital 75 | $1,464,000 |
Income_Tax_Narrative_Details
Income Tax (Narrative) (Details) (USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2014 |
Income Tax 1 | $4,802 |
Income Tax 2 | 246 |
Income Tax 3 | 9,530 |
Income Tax 4 | 8,874 |
Income Tax 5 | 9,683 |
Income Tax 6 | 9,040 |
Income Tax 7 | 1,100 |
Income Tax 8 | 1,098 |
Income Tax 9 | 20 |
Income Tax 10 | 194 |
Income Tax 11 | 170 |
Income Tax 12 | 145 |
Income Tax 13 | 154 |
Income Tax 14 | 193 |
Income Tax 15 | 129 |
Income Tax 16 | 95 |
Income Tax 17 | 4,805 |
Income Tax 18 | $4,354 |
Related_Party_Transactions_Nar
Related Party Transactions (Narrative) (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Related Party Transactions 1 | $29,000 |
Related Party Transactions 2 | 10,000 |
Related Party Transactions 3 | 0 |
Related Party Transactions 4 | 39,000 |
Related Party Transactions 5 | 43,000 |
Related Party Transactions 6 | 29,000 |
Related Party Transactions 7 | 17,000 |
Related Party Transactions 8 | 10,000 |
Related Party Transactions 9 | 187,000 |
Related Party Transactions 10 | $80,000 |
Subsequent_Events_Narrative_De
Subsequent Events (Narrative) (Details) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2014 | |
USD ($) | CAD | |
M | ||
Subsequent Events 1 | 500,000 | |
Subsequent Events 2 | 430,000 | |
Subsequent Events 3 | 3,500,000 | |
Subsequent Events 4 | 3,000,000 | |
Subsequent Events 5 | 50.00% | 50.00% |
Subsequent Events 6 | 3,000,000 | |
Subsequent Events 7 | 2,600,000 | |
Subsequent Events 8 | 6 | 6 |
Subsequent Events 9 | 12 | 12 |
Subsequent Events 10 | 6 | 6 |
Subsequent Events 11 | 60 | 60 |
Subsequent Events 12 | 2 | 2 |
Subsequent Events 13 | 1,500,000 | 1,500,000 |
Subsequent Events 14 | $1,600,000 | |
Subsequent Events 15 | 20.00% | 20.00% |
Schedule_of_Estimated_Useful_L
Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Y | |
Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 1 | 20.00% |
Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 2 | 30.00% |
Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 3 | $5 |
Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 4 | 10 |
Schedule_of_Leasehold_Improvem
Schedule of Leasehold Improvements and Equipment (Details) (USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2014 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 1 | $520 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 2 | 0 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 3 | 520 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 4 | 446 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 5 | 570 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 6 | 329 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 7 | 241 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 8 | 121 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 9 | 57 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 10 | 42 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 11 | 15 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 12 | 11 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 13 | 63 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 14 | 63 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 15 | 0 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 16 | 0 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 17 | 207 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 18 | 0 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 19 | 207 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 20 | 10 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 21 | 1,417 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 22 | 434 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 23 | 983 |
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 24 | $588 |
Schedule_of_Stock_by_Class_Det
Schedule of Stock by Class (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Capital Stock Schedule Of Stock By Class 1 | $0 |
Capital Stock Schedule Of Stock By Class 2 | 100,000,000 |
Capital Stock Schedule Of Stock By Class 3 | 0.00001 |
Capital Stock Schedule Of Stock By Class 4 | 20,000,000 |
Capital Stock Schedule Of Stock By Class 5 | 0.00001 |
Capital Stock Schedule Of Stock By Class 6 | 0 |
Capital Stock Schedule Of Stock By Class 7 | 63,465,255 |
Capital Stock Schedule Of Stock By Class 8 | 60,984,267 |
Capital Stock Schedule Of Stock By Class 9 | 635,000 |
Capital Stock Schedule Of Stock By Class 10 | $610,000 |
Schedule_of_480000_Stock_Optio
Schedule of 480,000 Stock Options Valuation - April 24, 2013 (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Y | |
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 1 | 78.00% |
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 2 | 3.83 |
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 3 | 0.34% |
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 4 | $0 |
Schedule_of_200000_Stock_Optio
Schedule of 200,000 Stock Options Valuation - April 24, 2013 (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Y | |
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 1 | 77.00% |
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 2 | 3.13 |
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 3 | 0.34% |
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 4 | $0 |
Schedule_of_35000_Stock_Option
Schedule of 35,000 Stock Options Valuation - August 6, 2013 (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Y | |
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 1 | 75.00% |
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 2 | 3.13 |
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 3 | 0.62% |
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 4 | $0 |
Schedule_of_75000_Stock_Option
Schedule of 75,000 Stock Options Valuation - December 3, 2013 (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Y | |
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - December 3, 2013 1 | 67.00% |
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - December 3, 2013 2 | 3.13 |
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - December 3, 2013 3 | 0.58% |
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - December 3, 2013 4 | $0 |
Schedule_of_100000_Stock_Optio
Schedule of 100,000 Stock Options Valuation - December 3, 2013 (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Y | |
Additional Paid-in Capital Schedule Of 100,000 Stock Options Valuation - December 3, 2013 1 | 67.00% |
Additional Paid-in Capital Schedule Of 100,000 Stock Options Valuation - December 3, 2013 2 | 3.13 |
Additional Paid-in Capital Schedule Of 100,000 Stock Options Valuation - December 3, 2013 3 | 0.58% |
Additional Paid-in Capital Schedule Of 100,000 Stock Options Valuation - December 3, 2013 4 | $0 |
Schedule_of_100000_Stock_Optio1
Schedule of 100,000 Stock Options Valuation - December 6, 2013 (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Y | |
Additional Paid-in Capital Schedule Of 100,000 Stock Options Valuation - December 6, 2013 1 | 67.00% |
Additional Paid-in Capital Schedule Of 100,000 Stock Options Valuation - December 6, 2013 2 | 3.13 |
Additional Paid-in Capital Schedule Of 100,000 Stock Options Valuation - December 6, 2013 3 | 0.64% |
Additional Paid-in Capital Schedule Of 100,000 Stock Options Valuation - December 6, 2013 4 | $0 |
Schedule_of_175000_Stock_Optio
Schedule of 175,000 Stock Options Valuation - December 8, 2014 (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Y | |
Additional Paid-in Capital Schedule Of 175,000 Stock Options Valuation - December 8, 2014 1 | 63.00% |
Additional Paid-in Capital Schedule Of 175,000 Stock Options Valuation - December 8, 2014 2 | 3.13 |
Additional Paid-in Capital Schedule Of 175,000 Stock Options Valuation - December 8, 2014 3 | 1.10% |
Additional Paid-in Capital Schedule Of 175,000 Stock Options Valuation - December 8, 2014 4 | $0 |
Schedule_of_Stock_Option_Activ
Schedule of Stock Option Activity to Employees and Directors[Table Text Block] (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 1 | $915,588 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 2 | 0.59 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 3 | 990,000 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 4 | 0.61 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 5 | -45,000 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 6 | -0.48 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 7 | -238,088 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 8 | -0.8 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 9 | -25,000 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 10 | -0.31 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 11 | 1,597,500 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 12 | 0.58 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 13 | 175,000 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 14 | 0.53 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 15 | -517,500 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 16 | -0.64 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 17 | -125,000 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 18 | -0.61 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 19 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 20 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 21 | $1,130,000 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 22 | 0.54 |
Schedule_of_Stock_Option_Activ1
Schedule of Stock Option Activity to Consultant's (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 1 | $150,000 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 2 | 0.55 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 3 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 4 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 5 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 6 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 7 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 8 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 9 | -50,000 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 10 | -0.47 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 11 | 100,000 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 12 | 0.59 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 13 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 14 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 15 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 16 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 17 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 18 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 19 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 20 | 0 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 21 | $100,000 |
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 22 | 0.59 |
Schedule_of_Sharebased_Compens
Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1 | 0.37 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2 | $75,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3 | 0.04 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4 | 0.02 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5 | 75,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6 | 0.03 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 7 | 0.45 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 8 | 100,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 9 | 0.03 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 10 | 0.04 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 11 | 100,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 12 | 0.05 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 13 | 0.51 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 14 | 20,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 15 | 0.04 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 16 | 0.01 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 17 | 20,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 18 | 0.01 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 19 | 0.52 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 20 | 50,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 21 | 0.06 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 22 | 0.02 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 23 | 50,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 24 | 0.03 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 25 | 0.52 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 26 | 275,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 27 | 0.89 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 28 | 0.12 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 29 | 137,500 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 30 | 0.08 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 31 | 0.53 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 32 | 175,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 33 | 0.71 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 34 | 0.08 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 35 | 0 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 36 | 0 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 37 | 0.54 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 38 | 145,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 39 | 0.23 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 40 | 0.06 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 41 | 145,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 42 | 0.09 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 43 | 0.55 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 44 | 50,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 45 | 0.02 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 46 | 0.02 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 47 | 50,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 48 | 0.03 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 49 | 0.58 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 50 | 35,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 51 | 0.1 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 52 | 0.02 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 53 | 17,500 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 54 | 0.01 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 55 | 0.6 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 56 | 55,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 57 | 0.13 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 58 | 0.03 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 59 | 55,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 60 | 0.04 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 61 | 0.62 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 62 | 50,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 63 | 0.04 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 64 | 0.03 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 65 | 50,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 66 | 0.04 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 67 | 0.65 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 68 | 200,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 69 | 0.54 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 70 | 0.11 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 71 | 150,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 72 | 0.11 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 73 | 1,230,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 74 | 2.85 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 75 | 0.54 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 76 | 17,865 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 77 | 850,000 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 78 | 0.54 |
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 79 | $17,865 |
Schedule_of_Warrants_Valuation
Schedule of Warrants Valuation - December 16, 2013 (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Y | |
Additional Paid-in Capital Schedule Of Warrants Valuation - December 16, 2013 1 | 80.00% |
Additional Paid-in Capital Schedule Of Warrants Valuation - December 16, 2013 2 | 5 |
Additional Paid-in Capital Schedule Of Warrants Valuation - December 16, 2013 3 | 1.55% |
Additional Paid-in Capital Schedule Of Warrants Valuation - December 16, 2013 4 | $0 |
Schedule_of_05_million_Warrant
Schedule of 0.5 million Warrants Valuation - December 16, 2013 (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Y | |
Additional Paid-in Capital Schedule Of 0.5 Million Warrants Valuation - December 16, 2013 1 | 72.00% |
Additional Paid-in Capital Schedule Of 0.5 Million Warrants Valuation - December 16, 2013 2 | 4 |
Additional Paid-in Capital Schedule Of 0.5 Million Warrants Valuation - December 16, 2013 3 | 1.12% |
Additional Paid-in Capital Schedule Of 0.5 Million Warrants Valuation - December 16, 2013 4 | $0 |
Schedule_of_Stockholders_Equit
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1 | $6,104,165 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2 | 0.5938 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3 | 7,920,346 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4 | 0.5646 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5 | 475,221 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6 | 0.5646 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 7 | -3,098,500 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 8 | -0.4741 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9 | -257,500 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10 | -0.4741 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 11 | 11,143,732 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12 | 0.6079 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 13 | -2,480,988 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 14 | -0.6524 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 15 | -1,431,621 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 16 | -0.74 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 17 | $7,231,123 |
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 18 | 0.5646 |
Schedule_of_Effective_Income_T
Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2014 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 1 | ($429) |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 2 | -442 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 3 | 238 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 4 | 278 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 5 | 9 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 6 | 11 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 7 | 26 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 8 | 56 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 9 | 181 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 10 | 142 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 11 | -25 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 12 | -45 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 13 | 0 |
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 14 | $0 |
Schedule_of_Deferred_Tax_Asset
Schedule of Deferred Tax Assets and Liabilities (Details) (USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2014 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 1 | $9 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 2 | 14 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 3 | 2,582 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 4 | 2,407 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 5 | 1,355 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 6 | 1,283 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 7 | 1,102 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 8 | 1,098 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 9 | 5,048 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 10 | 4,802 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 11 | -5,048 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 12 | -4,802 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 13 | 0 |
Income Tax Schedule Of Deferred Tax Assets And Liabilities 14 | $0 |
Schedule_of_Cash_Flow_Suppleme
Schedule of Cash Flow, Supplemental Disclosures (Details) (USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2014 |
Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 1 | $5 |
Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 2 | $5 |